Protocol No.: VX20-121-103

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation
Principal Investigator
Moffett, Kathryn S
Phase
III
Age Group
Both
Applicable Disease Site
Cystic Fibrosis
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Tammy Clark, RN
Study Coordinator/Research Nurse
Phone: +1 304-293-5264

View on ClinicalTrials.gov